Parallax Volatility Advisers
LXRX icon

Parallax Volatility Advisers’s Lexicon Pharmaceuticals LXRX Stock Holding History

Parallax Volatility Advisers’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-417,500
Closed -$5.13M – 4534
2017
Q3 		$5.13M Buy
+417,500
New +$6.17M 0.01% 563

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Parallax Volatility Advisers's LXRX Position: Q2 2022 in Review

Parallax Volatility Advisers sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2022, closing a stake of 19,265 shares — an estimated $40K sold.

Parallax Volatility Advisers first reported a position in LXRX in Q3 2017 and held it in 6 quarters. The position peaked at $4.31M in Q3 2017. 86 funds tracked by Wall St. Rank hold LXRX as of Q2 2022.

  • Parallax Volatility Advisers reported no remaining Lexicon Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Parallax Volatility Advisers sold 19,265 Lexicon Pharmaceuticals shares in Q2 2022, an estimated $40K.
  • Parallax Volatility Advisers first reported a position in Lexicon Pharmaceuticals in Q3 2017 and held it in 6 quarters.
  • Parallax Volatility Advisers's Lexicon Pharmaceuticals position peaked at $4.31M in Q3 2017.
  • 86 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2022.

Based on Parallax Volatility Advisers's 13F filing for Q2 2022, filed 15 Aug 2022.